Clinical Trials
Category Added in a WPeMatico Campaign
-
Safety and tolerability of avacincaptad pegol in combination with ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration: results from a phase 1 and phase 2a study
CONCLUSIONS: Coadministration of ACP and ranibizumab in treatment-naïve patients with nAMD was well tolerated across different dosing regimens with no new safety issues based on results from two independent studies.
-
Effect of Bioptron light therapy on dryness of eyes in postmenopausal women: a randomized controlled trial
To examine the short-term therapeutic effects of Bioptron light therapy (BLT) on dry eye disease (DED) in postmenopausal women. Sixty postmenopausal women diagnosed with DED, aged 50-62 years with a body mass index ≤ 30 kg/m², were randomly assigned to two equal groups. The Bioptron group (n = 30) received BLT for 10 min, twice…
-
Treatment of peri-implant mucositis using an erythritol air-polishing or ultrasonic device: A randomized controlled trial
CONCLUSION: Both EAP and US effectively treated peri-implant mucositis with comparable overall efficacy. However, EAP showed superior potential in reducing deep pockets over the short term, though this finding required further validation.
-
Niacin Modulates Immune Responses in a Phase I Dose-Escalation Clinical Trial of Newly Diagnosed Glioblastoma
BACKGROUND AND OBJECTIVES: Glioblastoma, a highly aggressive and uniformly lethal brain tumor, resists current treatments and immunotherapies by creating a potently immunosuppressive microenvironment. The objective of this study was to determine whether niacin modulates systemic immunity in patients with newly diagnosed glioblastoma.
-
Selective Personality-Targeted Intervention and the Escalation of Substance Use During Adolescence: A Secondary Analysis of A Cluster-Randomized Clinical Trial
CONCLUSIONS AND RELEVANCE: This secondary analysis of a cluster-randomized clinical trial found that personality-targeted interventions protected against the escalation in substance use during adolescence, with similar effects for males and females.
-
Risk factors for revictimization during treatment in patients with co-occurring SUD and PTSD
Introduction: A host of cross-sectional studies have identified problematic substance use and post-traumatic stress symptoms as risk factors for repeated interpersonal violence (revictimization) in college samples. However, it remains unclear which factors are associated with revictimization for patients who meet diagnostic criteria for both substance use disorder (SUD) and post-traumatic stress disorder (PTSD). The identification…
-
Effect of early integration of supportive care in addition to standard care in patients with breast cancer: A randomised controlled trial
CONCLUSIONS: Early supportive care integration significantly reduces symptom burden, enhances psychological well-being, and lowers financial stress, supporting its inclusion as standard adjunct cancer care in developing countries, providing actionable evidence for policymakers in LMICs.
-
Leg compression for preventing hypotension after spinal anesthesia in elderly hip fracture patients
CONCLUSION: The application of medical compression stocking in elderly patients undergoing HF surgery demonstrated an ability to reduce the incidence of hypotension perioperatively and might prevent in-hospital hypotension-related complication.
-
Minimally Invasive Sacroiliac Joint Fusion Using 3D Printed Implants and a Lateral Approach: Safety and Effectiveness Assessments of Fusion Performed by Interventional Physicians in a Prospective Multicenter Single-Arm Clinical Study (The FICS Study)
CONCLUSIONS: Laterally placed SIJ fusion titanium alloy implants are a safe and effective treatment for patients with refractory SIJ dysfunction, as evidenced by significant improvements in pain and function, high rates of radiological fusion, and a favorable safety profile.
-
Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis of a phase 3 trial
CONCLUSION: Interrupted vunakizumab treatment reduced the clinical response and quality of life in patients with moderate-to-severe plaque psoriasis.